Immunomodulation and Tolerance Group (ITG)
Welcome to the Immunomodulation and Tolerance Group (ITG) Podcast Channel, led by Professor Mohamed Shamji at Imperial College London. Join us as we explore the forefront of allergy and immunology research, focusing on allergy immunotherapy and the science behind allergic diseases. Tune in for episodes on: - Key mechanisms in immune regulation, including different subsets of T and B cells and ILC2s in allergy and immunotherapy - How our biomarker and discovery platforms enable end-to-end research, from basic science to clinical trials - Translational breakthroughs in allergen immunotherapy and novel treatment approaches for allergies - Insights from major clinical trials and collaborative projects with academic, pharmaceutical, and biotech partners - Special episodes with external collaborators introducing joint research and new therapeutic directions - The role of data science, AI, and machine learning in uncovering mechanisms and biomarkers Whether you’re a scientist, clinician, student, or simply curious about the future of allergy treatment, the ITG Podcast Channel brings you expert perspectives and the latest advances in immunomodulation and tolerance. Listen to our journey to transform allergy and immunology research here!
Listen on:
Episodes
6 days ago
6 days ago
Keywords
Peanut allergy, VLP peanut therapy, Oral immunotherapy, Immune tolerance, Clinical trials, Allergy treatment, Immunology, Safety profile, Food allergies, Innovative therapies
Summary
In this conversation, Wayne Shreffler and Mo Shamji discuss the challenges and advancements in peanut allergy treatment. They explore current FDA-approved therapies, the innovative VLP peanut therapy, its mechanisms of action, safety profile, and the promising results from clinical trials. The discussion highlights the potential for a paradigm shift in allergy treatment towards inducing long-term immune tolerance.
Takeaways
Peanut allergy affects millions and poses severe health risks.
Current treatments include oral immunotherapy and Omalizumab.
OIT can induce immune modulation but has limitations.
VLP peanut therapy uses nanoparticles to promote tolerance.
VLP peanut is designed to be safe and non-reactive.
Early trials show promising safety and efficacy results.
The goal is to achieve sustained protection from allergies.
Immunological mechanisms are crucial for developing new therapies.
The future of allergy treatment may shift towards immune re-education.
Innovative platforms like VLP peanut could expand to other allergies.
Sound Bites
"We have two currently that are FDA approved."
"VLP peanut is designed to immunological tolerance."
"The data have been very reassuring."
Chapters
00:00 Introduction to ITG Podcast
02:20 Current treatment options for peanut allergy
04:51 Innovative Approaches: VLP Peanut Therapy
06:14 Mechanism of action of VLP peanut
07:49 Assessing the risk for immediate allergic reactions
08:47 VLP Peanut Phase 1 trial
09:53 Safety data from skin prick test
10:24 Repeated subcutaneous administration of VLP Peanut
11:35 Biomarker data for dose-dependent immune response
12:42 Future Directions and Paradigm Shifts in Peanut Allergy Treatment
13:57 Future research direction on VLP Peanut